MedTrace Logo

Combination Chemotherapy in Treating Women With Stage III Breast Cancer

NCT00002696 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-08-02

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Randomized phase III trial to compare cyclophosphamide, doxorubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in treating women with stage III breast cancer.

Conditions

Interventions

DRUG

CAF regimen

DRUG

CMF regimen

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

fluorouracil

DRUG

methotrexate

PROCEDURE

adjuvant therapy

PROCEDURE

conventional surgery

PROCEDURE

neoadjuvant therapy

RADIATION

radiation therapy

Sponsors & Collaborators

  • Grupo Oncologico Cooperativo del Sur

    lead OTHER

Principal Investigators

  • Bernardo A. Leone, MD · Unidad Oncologica Del Neuquen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-10-31

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002696 on ClinicalTrials.gov